EsoBiotec, a biotechnology company developing in vivo cell therapies, is to be acquired by AstraZeneca. AstraZeneca will make an initial payment of $425m on deal closing, and up to $575m in contingent consideration based on development and regulatory milestones. The EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform is designed to empower the immune system to attack […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!